GlassScriptPhysician profile
Joseph A Grillo
NPI 1437449246
$87,903.75
in general payments reported to CMS, 2019-2025
47 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,629 · 2020: $2,171 · 2021: $3,525 · 2022: $4,403 · 2023: $6,594 · 2024: $31K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $12K · Travel and Lodging: $290 · Education: $188 · Consulting Fee: $49.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,939.08 |
| Food and Beverage | $11,708.99 |
| Travel and Lodging | $289.52 |
| Education | $188.42 |
| Consulting Fee | $49.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $66,464.35 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $5,219.70 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $4,287.45 | 2019-2025 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $1,210.00 | 2019-2025 | |
| Genzyme Corporation | $1,189.14 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $1,142.47 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $972.04 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Amgen INC. | $795.42 | 2021-2025 | Tezspire, Actimmune |
| Optinose US, INC. | $676.06 | 2019-2025 | |
| Leo Pharma INC. | $623.98 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $571.65 | 2019-2025 | Xembify |
| Kaleo, INC. | $528.62 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $478.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.25 | 2019-2023 | Spiriva Respimat |
| Incyte Corporation | $371.10 | 2021-2025 | Opzelura |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $330.92 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Alk-Abello, INC | $275.65 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Genentech USA, INC. | $268.73 | 2019-2025 | Xolair |
| Abbvie INC. | $211.72 | 2021-2023 | |
| Octapharma USA, INC. | $202.98 | 2021-2025 | Cutaquig, Panzyga |
| Sanofi-Aventis U.S. LLC | $129.98 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $129.02 | 2021-2022 | |
| Aytu Biopharma, INC. | $122.18 | 2022-2024 | Karbinal |
| Blueprint Medicines Corporation | $114.24 | 2023-2025 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $107.39 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $94.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.45 | 2019-2022 | |
| Covis Pharma Gmbh | $67.94 | 2019 | |
| Galderma Laboratories, L.P. | $67.64 | 2025 | Nemluvio |
| Genentech, INC. | $65.75 | 2019 | |
| Shire North American Group INC | $63.87 | 2019 | |
| Horizon Therapeutics Plc | $59.91 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $52.38 | 2023-2024 | Ryaltris |
| Organon LLC | $49.62 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $49.16 | 2025 | |
| Circassia INC. | $48.61 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $46.16 | 2025 | Sajazir |
| Lilly USA, LLC | $40.94 | 2025 | Ebglyss |
| Phadia US INC. | $36.74 | 2021-2025 | Immunocap |
| Ionis Pharmaceuticals, INC. | $36.56 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $35.97 | 2022-2023 | Ruconest |
| Biocryst Pharmaceuticals, INC. | $35.81 | 2020 | |
| Merck Sharp & Dohme LLC | $30.21 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $25.77 | 2025 | Neffy |
| Novo Nordisk INC | $24.83 | 2023 | Ozempic, Rybelsus |
| Greer Laboratories, INC. | $19.12 | 2025 | Oralair |
| Arcutis Biotherapeutics, INC. | $15.43 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Grillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.